Time
Topic
Speaker
Times shown are in Eastern Time.
Agenda subject to change.
2026 Agenda
Saturday, November 7
Saturday, November 7
7:00–7:55 AM
Registration and Breakfast
7:55–8:00 AM
Welcome and Introductions
- Co-Chair: Suresh S. Ramalingam, MD, FACP, FASCO
- Co-Chair: Ticiana Leal, MD
8:00-8:20 AM
20th Anniversary Keynote Presentation: Early-Stage NSCLC: A Therapeutic Revolution 20 Years in the Making
Plenary 1: Early-Stage NSCLC/Locally Advanced NSCLC: Multidisciplinary Integration of Neoadjuvant, Surgical, and Adjuvant Therapies
Co-Chairs: Ioana Bonta, MD and Onkar V. Khullar, MD, MSc
8:20–8:35 AM
Targeted Therapies Move Earlier: Advances in EGFR, ALK, and RET-Positive NSCLC
- Paul Bunn, MD
8:35–8:50 AM
Neoadjuvant vs. Adjuvant Therapy: Is the Debate Over?
- Jamie E. Chaft, MD
8:50–9:05 AM
What Is ‘Resectable’ Lung Cancer Today?
- Onkar V. Khullar, MD, MSc
9:05–9:20 AM
Practical Applications of Advanced Diagnostic Approaches in Lung Cancer
- Abesh Niroula, MBBS, MD
9:20–9:35 AM
Multidisciplinary Team (MDT) Case Panel Discussion
- Faculty Panelists: Rachel Medbery, MD
9:35–9:50 AM
Panel Discussion and Audience Q&A
9:50–10:35 AM
Morning Symposium and Exhibits
Plenary 2: Advanced NSCLC/SCLC
Co-Chairs: Mohan Krishnamachary, MD and Aparna Kesarwala, MD, PhD
10:35–10:50 AM
Immunotherapy for Advanced NSCLC: New Agents and Novel Combinations
10:50–11:05 AM
Small Cell Lung Cancer: Expanding Options, More Hope
- Ticiana Leal, MD
11:05–11:20 AM
Locally Advanced NSCLC: Have We Hit the Ceiling?
- Sibo Tian, MD
11:20–11:45 AM
MRD Status Should Guide Adjuvant Therapy
- Yes:
- No: Conor Steuer, MD
11:45 AM–12:00 PM
Panel Discussion and Audience Q&A
12:00–12:45 PM
Lunch Symposium and Exhibits
Plenary 3: Targeted Therapy in Advanced NSCLC
Co-Chairs: Trevor Feinstein, MD and Kelsey Pan, MD
12:45–1:00 PM
EGFR-Mutated NSCLC: Common and Exon 20 Insertion Mutations
- Suresh S. Ramalingam, MD, FACP, FASCO
1:00–1:15 PM
KRAS-Mutated NSCLC: The Next Targeted Therapy Frontier
- Gregory J. Riely, MD, PhD
1:15–1:40 PM
Are ADCs Truly Transformational in NSCLC?
- Yes: Joshua K. Sabari, MD
- No: Rachel E. Sanborn, MD
1:40–1:55 PM
Panel Discussion and Audience Q&A
1:55–2:10 PM
Afternoon Break and Exhibits
Plenary 4: Targeted Therapy in Advanced NSCLC II and Rare Thoracic Malignancies
Co-Chairs: Steve McCune, MD and Laercio Da Silva, MD
2:10–2:25 PM
HER2-Mutated NSCLC: New First-Line Therapy and Other Options
- John V. Heymach, MD, PhD
2:25–2:40 PM
Targeting ALK and Managing Resistance
- Shirish M. Gadgeel, MBBS, FASCO
2:40–2:55 PM
ROS1 Fusion: Novel Agents and New Insights
- Jennifer Carlisle, MD
2:55–3:10 PM
Beyond the Big Drivers: Targeting RET, MET, and BRAF
- Ryan Gentlzer, MD
3:10–3:25 PM
Brain Metastases in NSCLC: Rethinking Management in the Targeted Therapy Era
3:25–3:40 PM
Panel Discussion and Audience Q&A
3:40–3:50 PM
Closing Remarks and Adjourn